

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



November 15, 2024

NEWS RELEASE

Company name: TMS Co., Ltd.
Name of representative: Takuro Wakabayashi, Chief Executive Officer
(Securities code 4891; Growth Market)

TMS Co., Ltd. CEO Takuro Wakabayashi Interviewed on US Internet News Media "Biotech TV"

TMS Co., Ltd. (TSE: 4891) (the "Company"), a clinical-stage biopharmaceutical company focused on discovering and accelerating the development of transformative medicines in areas of high unmet medical need, today announced that Takuro Wakabayashi, Chief Executive Officer, was interviewed on Biotech TV, hosted by biotechnology veteran, Brad Loncar.

Summary of the interview

Takuro Wakabayashi, Chief Executive Officer of TMS Co., Ltd., provided an overview of the Company and highlighted JX10 (TMS-007) as a potential next generation treatment for acute ischemic stroke, an area with great unmet medical need that has not seen a new approved drug in more than 30 years. Additionally, the Company discussed its emerging pipeline programs that include hypertension, kidney injury, and spinal cord injury.

The full interview can be found here:

[Tokyo based TMS has a lead program that aims to be the first new medicine for acute ischemic stroke in decades](#)

About Biotech TV

Biotech TV is an internet media that covers news, stories, educational video content, etc. in the biotechnology sector, and has approximately 20,000 followers on LinkedIn and approximately 7,000 followers on X (Twitter).

About TMS Co., Ltd.

TMS Co., Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of transformative medicines for the treatment of serious diseases in areas of high unmet medical need. The Company's pipeline consists of a family of small molecule compounds called SMTPs (Stachybotrys Microspora Triprenyl Phenols) derived from a fungus. TMS' lead program, TMS-007 (JX10), has demonstrated efficacy and safety in its Phase 2a study for the treatment of acute ischemic stroke. The Company's robust pipeline also includes programs in resistant or uncontrolled hypertension, acute kidney injury, and spinal cord injury. TMS continues to explore new pipeline products by leveraging its established partnerships with leading academic institutions in Japan, with the intention to build a bridge between academic discoveries and the global pharmaceutical market. For more information about TMS, please visit <https://www.tms-japan.co.jp/en/>

Investor and Media Contact:

ir@tms-japan.co.jp

Kevin Lui

Precision AQ

Kevin.Lui@precisionaq.com

End